|
|
|
| Analysis of distribution and drug resistance of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae |
| LI Li LIU Dan WANG Jiahe▲ |
| Department of Geriatrics, Shengjing Hospital Affiliated to China Medical University, Liaoning Province, Shenyang 110004, China |
|
|
|
Abstract Objective To analyze the clinical distribution and drug resistance of extended-spectrum beta-lactamase (ESBLs)-producing Klebsiella pneumoniae in hospitalized patients in Shengjing Hospital Affiliated to China Medical University ("our hospital" for short), in order to provide references for therapy of infections. Methods ESBLs-producing Klebsiella pneumoniae isolated in our hospital from January to December 2015 were collected. The bacteria identification and drug sensitivity test were performed by the VITEK 2 Compact. The ESBLs preliminary screening and the phenotypic confirmatory test were taken according to the guideline of CLSI, and at the same time, the results of the drug sensitivity test were analyzed. Results 302 strains of ESBLs-producing Klebsiella pneumoniae were isolated, which were mostly isolated from sputum samples (38.74%), followed by blood (28.81%) and urine (13.91%). The bacteria were mainly distributed in Paediatrics Department (53.97%) and General Surgery Department (7.95%). The drug resistances of ESBLs-producing Klebsiella pneumoniae to Ampicillin, Cefazolin, Piperacillin, Ceftriaxone, Cefotaxime in hospitalized patients were more than 95%, and the resistance rate to carbapenemes was lower, less than 3%. Conclusion The isolated ESBLs-producing Klebsiella pneumoniae in hospitalized patients are highly resistant to the commonly used antibiotics, and the treatment is difficult. Therefore, the drug sensitive test should be strengthened to direct clinical rational use of antibiotics.
|
|
|
|
|
|
[1] Kazmierczak KM，Lob SH，Hoban DJ，et al. Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America，2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends [J]. Diagn Microbiol Infect Dis，2015，82（3）：209-214.
[2] Peralta G，Lamelo M，Alvarez-García P，et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study [J]. BMC Infect Dis，2012，12（1）：245.
[3] Gholipour A，Soleimani N，Shokri D，et al. Phenotypic and Molecular Characterization of Extended-Spectrum β-Lactamase Produced by Escherichia coli，and Klebsiella pneumoniae Isolates in an Educational Hospital [J]. Jundishapur J Microbiol，2014，7（10）：e11758.
[4] Mansury D，Motamedifar M，Sarvari J，et al. Antibiotic susceptibility pattern and identification of extended spectrum β-lactamases （ESBLs） in clinical isolates of Klebsiella pneumoniae from Shiraz，Iran [J]. Iran J Microbiol，2016，8（1）：55-61.
[5] Somily AM，Habib HA，Absar MM，et al. ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in Saudi Arabia.[J]. J Infect Dev Ctries，2014，8（9）：1129-1136.
[6] 尚红，王毓三，申子瑜.全国临床检验操作规程[M].北京：人民卫生出版社，2015.
[7] 李小鹏，王治国.美国临床实验室标准化委员会标准与指南[J].中华检验医学杂志，2001，24（4）：251-252.
[8] 张长虹，孟存仁，晓英.产ESBLs大肠埃希菌和肺炎克雷伯菌耐药性分析及TEM、SHV基因检测[J].国际检验医学杂志，2015，36（5）：583-585.
[9] Shaikh S，Fatima J，Shakil S，et al. Antibiotic resistance and extended spectrum beta-lactamases：Types，epidemiology and treatment [J]. Saudi J Biol Sci，2015，22（1）：90-101.
[10] Van Aken S，Lund N，Ahl J，et al. Risk factors，outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia [J]. Scand J Infect Dis，2014，46（11）：753-762.
[11] Giske CG，Sundsfjord AS，Kahlmeter G，et al. Redefining extended-spectrum beta-lactamases：balancing science and clinical need [J]. J Antimicrob Chemother，2009，63（1）：1-4.
[12] 朱瑞琪，张蕴莉，张淑芹，等.2011-2013年某综合性医院产ESBLs 细菌的分布及耐药动态监测[J].现代预防医学，2015，42（18）： 3450-3453.
[13] Biedenbach DJ，Bouchillon SK，Hoban DJ，et al. Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam：report from the Study for Monitoring Antimicrobial Resistance Trends（SMART 2009-2011）[J]. Diagn Microbiol Infect Dis，2014，79（4）：463-467.
[14] Leistner R，Gürntke S，Sakellariou C，et al. Bloodstream infection due to extended-spectrum beta-lactamase（ESBL）-positive K. pneumoniae and E. coli：an analysis of the disease burden in a large cohort [J]. Infection，2014， 42（6）：991-997.
[15] Vibet MA，Roux J，Montassier E，et al. Systematic analysis of the relationship between antibiotic use and extended-spectrum beta-lactamase resistance in Enterobacteriaceae in a French hospital：a time series analysis [J]. Eur J Clin Microbiol Infect Dis，2015，34（10）：1957-1963.
[16] 何丽芸，王应建，李季美.婴幼儿社区获得性肺炎克雷伯菌肺炎的临床特点及耐药分析[J].中国当代儿科杂志，2012，14（11）：827-829.
[17] 孙红，乔艳，郭普，等.肺炎克雷伯菌产ESBLs的检测及耐药性分析[J].中华全科医学，2011，9（5）：797-798.
[18] 孙立群，梁金花，李荣辉.大肠埃希菌与肺炎克雷伯菌耐药性及产ESBLs菌株的分析[J].中华医院感染学杂志，2013，23（2）：455-457.
[19] 李忠，曾金红，李亚，等.基层医院肺炎克雷伯菌的临床感染分布和耐药谱分析[J].中国医药科学，2015，5（3）：66-69.
[20] Udomsantisuk N，Nunthapisud P，Tirawatanapong T，et al. Molecular characterization of extended spectrum beta-lactamase among clinical isolates Escherichia coli and Klebsiella pneumoniae [J]. J Med Assoc Thai，2011，94（12）：1504-1512.
[21] 唐景云，秦晓林.ESBLs在大肠埃希菌、肺炎克雷伯菌和阴沟肠杆菌中的检出率及耐药情况比较[J].中国医药科学，2016，6（3）：175-178.
[22] Kaftandzieva A，Trajkovska-Dokic E，Panovski N. Prevalence and molecular characterization of Extended Spectrum Beta-Lactamases（ESBLs）producing Escherichia Coli and Klebsiella Pneumoniae.[J]. Prilozi，2011，32（2）：129-141.
[23] Yadav KK，Adhikari N，Khadka R，et al. Multidrug resistant Enterobacteriaceae and extended spectrum β-lactamase producing Escherichia coli：a cross-sectional study in National Kidney Center，Nepal [J]. Antimicrob Resist Infect Control，2015，4（1）：42. |
|
|
|
